Chitosan-Zinc as an Immunological Adjuvant

Information

  • Research Project
  • 6443719
  • ApplicationId
    6443719
  • Core Project Number
    R43AI051031
  • Full Project Number
    1R43AI051031-01
  • Serial Number
    51031
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/15/2002 - 22 years ago
  • Project End Date
    6/30/2003 - 21 years ago
  • Program Officer Name
    PROGRAIS, LAWRENCE J.
  • Budget Start Date
    7/15/2002 - 22 years ago
  • Budget End Date
    6/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/1/2002 - 22 years ago
Organizations

Chitosan-Zinc as an Immunological Adjuvant

DESCRIPTION: (Provided by Applicant) An effective immunological adjuvant is one that is able to enhance both antibody and cell mediated immune responses. Alum is the only adjuvant widely licensed for human use and is reported as stimulating effective T-helper cell type 2 (Th-2) like responses. Th-2 responses are typified by production of predominately IgG1, IgE and the cytokines IL-4, IL-5, IL-6 and IL-10. In contrast adjuvants such as Complete Freund?s adjuvant, stimulate strong antibody responses with a preponderance of IgG2a. This type of response is indicative of a Th-1 response and is associated with the presence of cell mediated immunity, delayed type hypersensitivity, induction of complement fixing and IgA antibodies and the cytokines IFN-gamma, IL-2 and IL-12. Desired adjuvants, especially for poorly immunogenic, subunit, recombinant protein and synthetic peptide and carbohydrate antigens, are those capable of stimulating Th-1 immune responses. In this study we will characterize the cytokine and specific antibody response using a new adjuvant developed at Zonagen. We believe this adjuvant, which was developed to combine the unique immune modulating properties of chitosan and zinc, will have several advantages in the preparation of vaccines. PROPOSED COMMERCIAL APPLICATION: Products, such as improved adjuvants, that will enhance the immune response to poorly immunogenic antigens, should be widely received and commercially profitable.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    98625
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:98625\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ZONAGEN, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    THE WOODLANDS
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    77380
  • Organization District
    UNITED STATES